Key result
A home-based advance care programme significantly reduced mean heart failure hospitalisations from 2.0 to 0.6 episodes per patient and all-cause hospitalisations from 3.6 to 1.0 episodes per patient.
Why the study?
Does a home-based advance care programme reduce hospitalisations in patients with end-stage heart failure?
Observational (n=44)
No
Does a home-based advance care programme reduce hospitalisations in patients with end-stage heart failure?
Absolute Event Rate: 0.6% vs 2%
p-value: p=<0.0001
A home-based advance care programme significantly reduced all-cause and heart failure hospitalizations in patients with end-stage heart failure.
Supports incorporating home-based ACP into end-stage HF care; leaves open need for RCTs to confirm benefits.
Introduction: In end-stage heart failure (HF) that is not eligible for mechanical assist device or heart transplant, palliative care serves to maximise symptom control and quality of life. We sought to evaluate the impact of home-based advance care programme (ACP) on healthcare utilisation in end-stage HF patients. Materials and Methods: Prospectively collected registry data on all end-stage HF recruited into ACP between July 2008 and July 2010 were analysed. Chart reviews were conducted on HF database and hospital electronic records. Phone interview and home visit details by ACP team were extracted to complete data entry. HF and all-cause hospitalisations 1 year before, and any time after ACP inception were defined as events. For the latter analysis, follow-up duration adjustment to event episodes was performed to account for death less than a year. Results: Forty-four patients (mean age 79 years, 39% men) were followed up for 15±8 months. Fifty-seven percent had diabetes, 80% ischaemic heart disease, and 60% chronic kidney disease. All reported functional class III/IV at enrolment. Mean serum sodium was 136±6 mmol/L, and creatinine 186±126 mmol/L. Thirty (68%) died within the programme. Mean time to death was 5.5 months. Mean all-cause and HF hospitalisations were 3.6 and 2.0 per patient before enrolment, but improved to 1.0 and 0.6 respectively after ACP. Thirty-six (71%) patients had fewer HF hospitalisations. When only those who survived more than a year were considered (n = 14), 10 (71%) and 9 (64%) experienced reduced HF (mean: 1.4 episodes per patient) and all-cause hospitalisations (mean: 2.2 episodes per patient) respectively. Conclusion: Home-based advance care programme is potentially effective in reducing healthcare utilisation of end-stage HF patients, primarily by reducing HF rehospitalisations, and in probably saving costs as well.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2013) conducted an observational in Advanced heart failure (n=44). Home-based advance care programme (ACP) vs. 1 year before ACP inception (within-patient comparison) was evaluated on Mean heart failure hospitalisations per patient (p=<0.0001). A home-based advance care programme significantly reduced mean heart failure hospitalisations from 2.0 to 0.6 episodes per patient and all-cause hospitalisations from 3.6 to 1.0 episodes per patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: